Continuum Advisory’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
Other funds holding CRNX
FCM
DCM
JT
Continuum Advisory's CRNX Position: Q2 2026 in Review
Continuum Advisory opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 39 shares worth $1.46K. The stake represents ﹤0.01% of the portfolio and ranks #1798 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in CRNX as recently as Q1 2025.
Continuum Advisory first reported a position in CRNX in Q1 2024 and has held it in 6 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Continuum Advisory held 39 shares of Crinetics Pharmaceuticals worth $1.46K as of Q2 2026.
- Crinetics Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
- Crinetics Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1798 holding.
- Continuum Advisory first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.